You are here

Kwatra, Madan Mohan

Overview:

The focus of this laboratory is on signaling through G protein-coupled receptors and clinical proteomics. These goals are currently being realized through three major projects: (1) Mechanism of signal transduction through substance P receptor in human glioblastomas; (2) Effect of age and diabetes on G protein-coupled receptors in human heart; and (3) Molecular basis of postoperative delirium in the elderly. Our studies use state-of-the-art techniques in protein biochemistry and molecular biology including DNA microarrays. A major goal of project #3 is to identify biomarkers of delirium in plasma using a proteomic approach including analyses by 2D-gel electrophoresis, mass spectrometry,SELDI/TOF (protein-chip), and protein microarrays.

Positions:

Associate Professor in Anesthesiology

Anesthesiology
School of Medicine

Associate Professor in Psychiatry and Behavioral Sciences

Psychiatry & Behavioral Sciences
School of Medicine

Associate Professor of Pharmacology & Cancer Biology

Pharmacology & Cancer Biology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

Ph.D. 1977

Ph.D. — University of Montreal (Canada)

Grants:

Evaluation of VAL-083, either alone or in combination with other agents, for its activity inhibition of glioblastoma subtypes (personalized drug development)

Administered By
Anesthesiology
AwardedBy
DelMar Pharmaceuticals, Inc.
Role
Principal Investigator
Start Date
April 14, 2017
End Date
June 30, 2020

Organization and Function of Cellular Structure

Administered By
Basic Science Departments
AwardedBy
National Institutes of Health
Role
Mentor
Start Date
July 01, 1975
End Date
June 30, 2020

Pharmacology Industry Internships for Ph.D. Students

Administered By
Pharmacology & Cancer Biology
AwardedBy
American Society for Pharmacology and Experimental Therapeutics
Role
Participating Faculty Member
Start Date
January 01, 2017
End Date
December 31, 2019

Evaluation of novel anti-cancer agents, either alone or in combination, for activity against glioblastoma subtypes: a personalized medicine approach

Administered By
Anesthesiology
AwardedBy
Genzada Pharmaceuticals, LLC
Role
Principal Investigator
Start Date
May 08, 2017
End Date
June 30, 2019

Curtana Pharmacueticals Sponsored Research Agreement

Administered By
Anesthesiology
AwardedBy
Curtana Pharmaceuticals, Inc.
Role
Principal Investigator
Start Date
December 16, 2016
End Date
June 30, 2017

Evaluation of AZD9291 in Glioblastoma patients with activated EGFR

Administered By
Anesthesiology
AwardedBy
National Institutes of Health
Role
Principal Investigator
Start Date
August 01, 2015
End Date
November 30, 2016

Targeting GBMs with Activated EGFR with third-generation, brain-penetrating AZD9291

Administered By
Anesthesiology
AwardedBy
Musella Foundation For Brain Tumor Research & Information, Inc
Role
Principal Investigator
Start Date
June 01, 2016
End Date
August 31, 2016

Summer Research fellowship for two undergraduate Pre-Med Students

Administered By
Anesthesiology
AwardedBy
Musella Foundation For Brain Tumor Research & Information, Inc
Role
Principal Investigator
Start Date
June 01, 2014
End Date
June 30, 2015

Truncated NK1R in GBM: Pharmacology and Relationship with Patient Survival

Administered By
Anesthesiology
AwardedBy
National Institutes of Health
Role
Principal Investigator
Start Date
July 01, 2012
End Date
June 30, 2015

Isolation of stem cells from glioblastoma xenografts with activated EGFR

Administered By
Anesthesiology
AwardedBy
Musella Foundation For Brain Tumor Research & Information, Inc
Role
Principal Investigator
Start Date
January 01, 2014
End Date
December 31, 2014

Molecular Basis of Postoperative Delirium in the Elderly

Administered By
Anesthesiology
AwardedBy
National Institutes of Health
Role
Principal Investigator
Start Date
January 15, 2003
End Date
June 30, 2010

Aging And G Protein Coupled Receptors In Human Heart

Administered By
Anesthesiology
AwardedBy
National Institutes of Health
Role
Principal Investigator
Start Date
September 01, 1998
End Date
August 31, 2006

Beta Adrenoceptors During Cardiopulmonary Bypass

Administered By
Anesthesiology, Cardiothoracic
AwardedBy
National Institutes of Health
Role
Co Investigator
Start Date
January 01, 1997
End Date
December 31, 2002

Function Of Human Substance P Receptor

Administered By
Anesthesiology
AwardedBy
National Institutes of Health
Role
Principal Investigator
Start Date
July 01, 1995
End Date
May 31, 2001

Desensitization Of B-Adrenoceptors During Cardiopulmonary

Administered By
Anesthesiology, Cardiothoracic
AwardedBy
National Institutes of Health
Role
Co-Principal Investigator
Start Date
January 01, 1997
End Date
December 31, 1999

Function Of Human Substances P Receptor

Administered By
Anesthesiology
AwardedBy
National Institutes of Health
Role
Principal Investigator
Start Date
July 01, 1995
End Date
May 31, 1999

Function Of Substance P Receptor

Administered By
Anesthesiology
AwardedBy
National Institutes of Health
Role
Principal Investigator
Start Date
July 01, 1995
End Date
May 31, 1999

Molecular Characterization Of Human Alc-Adrenergic Recept

Administered By
Anesthesiology, Cardiothoracic
AwardedBy
National Institutes of Health
Role
Co-Principal Investigator
Start Date
March 01, 1996
End Date
February 28, 1999

Transcriptional Regulation Of Human 1a-Adrenoceptors

Administered By
Anesthesiology, Cardiothoracic
AwardedBy
National Institutes of Health
Role
Co-Principal Investigator
Start Date
March 01, 1996
End Date
February 28, 1999

Excitatory Amino Acids In Ovine Fetal Brain Injury

Administered By
Anesthesiology, Women's
AwardedBy
National Institutes of Health
Role
Co-Principal Investigator
Start Date
October 01, 1996
End Date
December 31, 1998

Aging And G Protein-Coupled Receptor Signaling In Human

Administered By
Anesthesiology
AwardedBy
National Institutes of Health
Role
Principal Investigator
Start Date
September 30, 1996
End Date
September 29, 1997
Show More

Publications:

A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma.

Glioblastoma (GBM) is a deadly brain cancer, and all attempts to control it have failed so far. However, the future looks bright, as we now know the molecular landscape of GBM through the work of The Cancer Genome Atlas (TCGA) program. GBMs exhibit significant inter- and intratumoral heterogeneity, and to control this type of tumor, a personalized approach is required. One target, whose gene is amplified and mutated in a large number of GBMs, is the epidermal growth factor receptor (EGFR). But all attempts to target it have been unsuccessful. We attribute the reason for this failure to the molecular heterogeneity of EGFR in GBM, as well as to the poor brain penetration of previously tested EGFR-Tyrosine Kinase Inhibitors (EGFR-TKIs). In this review, we discuss the molecular heterogeneity of EGFR and provide rational preclinical and clinical guidelines for testing AZD9291, a third generation, irreversible EGFR-TKI with both a high affinity for EGFRvIII and excellent brain penetration.

Authors
Kwatra, MM
MLA Citation
Kwatra, MM. "A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma." Current cancer drug targets 17.3 (January 2017): 290-296. (Review)
PMID
28029074
Source
epmc
Published In
Current cancer drug targets
Volume
17
Issue
3
Publish Date
2017
Start Page
290
End Page
296
DOI
10.2174/1568009616666161227091522

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
1
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed research international 2017 (January 2017): 4790810-. (Review)
PMID
29057261
Source
crossref
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
End Page
6
DOI
10.1155/2017/4790810

Aprepitant for the Treatment of Chronic Refractory Pruritus

Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV). Recently, aprepitant has demonstrated effectiveness in several case series and open label trials in relieving pruritus for patients refractory to other treatments. Patients with pruritus associated with Sézary syndrome, mycosis fungoides, lung adenocarcinoma, breast carcinoma, sarcomas, metastatic solid tumors, chronic kidney disease, hyperuricemia, iron deficiency, brachioradial pruritus, and Hodgkin's lymphoma have experienced considerable symptom relief with short-term use of aprepitant (up to two weeks). Due to differences in reporting and evaluation of drug effects, the mechanism of aprepitant's role is difficult to understand based on the current literature. Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy.

Authors
He, A; Alhariri, JM; Sweren, RJ; Kwatra, MM; Kwatra, SG
MLA Citation
He, A, Alhariri, JM, Sweren, RJ, Kwatra, MM, and Kwatra, SG. "Aprepitant for the Treatment of Chronic Refractory Pruritus." BioMed Research International 2017 (2017): 1-6.
PMID
29057261
Source
epmc
Published In
BioMed Research International
Volume
2017
Publish Date
2017
Start Page
4790810
<